Authors

Alaaeldin Bashier

Publications 5

Research article Open access

Clinical Presentation, Treatment, and Outcome of Acromegaly in the United Arab Emirates

Khaled Al Dahmani, Bachar Afandi, Ali El Houni et al. · Oman Medical Journal · 2020 · 10.5001/omj.2020.114

Objectives: We sought to ascertain the clinical characteristics and control rate of acromegaly in the UAE. Methods: We conducted a multicenter retrospective analysis of all patients presenting with acromegaly to six endocrine centers in the UAE between November 2010 and December 2018. Demographic, clinical, biochemical …

Research article Open access

Lipid Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in Dubai: A Five-year Pattern

Elamin Abdelgadir, Maryam Alsaeed, Khadija Hafidh et al. · Oman Medical Journal · 2019 · 10.5001/omj.2019.58

Objectives: A key aspect for the prevention of vascular complications in diabetes is control of hyperlipidemia, and that has always been a global challenge. The prevalence of diabetes mellitus in the UAE is estimated to be 18.98%. However, despite this high prevalence, very few studies have evaluated the control of lip …

Research article Open access

Glycemic Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in the Emirate of Dubai, United Arab Emirates: A Five-Year Pattern

Fatheya Alawadi, Elamin Abdelgadir, Alaaeldin Bashier et al. · Oman Medical Journal · 2019 · 10.5001/omj.2019.04

Objectives: In the UAE, the comparative prevalence of diabetes is reported as 18.98%, but there are very few studies evaluating glycemic control. Attaining the optimum glycemic control has been a global challenge over the years. However, there is a trend of global improvement with the availability of newer options of a …

Research article Open access

Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes

Alaaeldin Bashier, Azza Abdulaziz Khalifa, Elamin Ibrahim Abdelgadir et al. · Oman Medical Journal · 2018 · 10.5001/omj.2018.21

Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) are a new class of antidiabetic drugs that might increase the risk of dehydration and hypoglycemia, particularly during the month of Ramadan in which Muslims abstain from eating and drinking for 14–16 hours daily. We aimed to provide real-life evidence abo …

Co-authors